Abstract:To assess the clinical efficacy and safety of neutralizing monoclonal antibodies (mABs) for outpatients with coronavirus disease 2019 (COVID-19). PubMed, Embase, Web of Science, Cochrane Library, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform (ICTRP) databases were searched from inception to July 19, 2021. Only randomized controlled trials (RCTs) that assessed the clinical efficacy and safety of neutralizing mABs in the treatment of COVID-19 outpatients were included. The Cochrane risk-of-bias tool was used to assess the quality of the included RCTs. The primary outcome was the risk of COVID-19-related hospitalization or emergency department (ED) visits. The secondary outcomes were the risk of death and adverse events (AEs). Five articles were included, in which 3309 patients received neutralizing mAB and 2397 patients received a placebo. A significantly lower rate of hospitalization or ED visits was observed among patients who received neutralizing mABs than those who received a placebo (1.7% vs. 6.5%, odds ratios (OR): 0.26; 95% confidence interval (CI): 0.19-0.36; I2 = 0%). In addition, the rate of hospitalization was significantly lower in the patients who received neutralizing mABs than in the control group (OR: 0.24; 95% CI: 0.17-0.34; I2 = 0%). The mortality rate was also significantly lower in the patients who received neutralizing mABs than in the control group (OR: 0.16; 95% CI: 0.05-0.58; I2 = 3%). Neutralizing mABs were associated with a similar risk of any AE (OR: 0.81; 95% CI: 0.64-1.01; I2 = 52%) and a lower risk of serious AEs (OR: 0.37; 97% CI: 0.19-0.72; I2 = 45%) compared with a placebo. Neutralizing mABs can help reduce the risk of hospitalization or ED visits in COVID-19 outpatients. For these patients, neutralizing mABs are safe and not associated with a higher risk of AEs than a placebo.

Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

COVID-19-neutralizing antibodies predict disease severity and survival

COVID-19 neutralizing antibodies predict disease severity and survival

Neutralizing antibodies for the treatment of COVID-19

Neutralization of SARS-CoV-2 Infection by Antibodies Targeting Diverse Epitopes

Neutralizing monoclonal antibodies for treatment of COVID-19

Neutralizing Monoclonal Antibodies Present New Prospects to Treat SARS-CoV-2 Infections

[Sars-Cov-2 Neutralizing Monoclonal Antibodies and Nanobodies: a Review].

Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals

Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies.

Opportunities and Challenges to the Use of Neutralizing Monoclonal Antibody Therapies for COVID-19

Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Monoclonal neutralizing antibodies against SARS-COV-2 S protein

Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial

The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations